bluuebunny/crossref_metadata_2025_split huggingface dataset:
Socioeconomic dilemmas of commercial markets for invasive species: lessons from lionfish in Mexico
Authors: Quintana Anastasia , Marcos Sergio , Malpica-Cruz Luis , Tamayo Lizbeth , Canto Noh José Ángel , Fernández-Rivera Melo Francisco , Fulton Stuart 
Published: December 2022

Abstract
“If you can’t beat ‘em, eat ‘em”: the development of commercial markets is an emerging strategy to control invasive species. This strategy may have fewer unintended ecological impacts than genetic modification and biological control; however, its unintended social impacts are poorly understood. We discuss the social dilemmas and opportunities created by commercializing invasive species, based on the experiences of fishing cooperatives’ harvest of invasive lionfish (Pterois sp.) in the Mexican Caribbean. In Cozumel, Mexico, a pilot commercial fishery began in 2012, and by 2015 had seemingly succeeded at reducing local lionfish abundance. However, three social dilemmas have accompanied this process. First, though designed to support sustainability, this market disproportionately benefits fishers that use fishing gear considered "unsustainable". Second, this strategy reinforces the narrative of fishers trapped in a “tragedy of the commons,” while simultaneously depending on the fishers’ participation. Finally, the programme's very success has led to its own demise, disproportionately affecting the programme's most invested participants. These and similar dilemmas may be inevitable when systems in place for sustainable resource harvest are repurposed for resource collapse. However, fishing cooperatives have managed to navigate these dilemmas in partnership with governmental and non-governmental organization (NGO) advocates to position themselves as conservation leaders.
Resistance to Prostaglandin E2 Promotes Monocyte Activation During Chronic HIV Infection
Authors: Di Diego Garcia Facundo , Cabrerizo Gonzalo , Paletta Ana , Pérez Paula S , Varese Augusto , Geffner Jorge , Bello Natalia , Fridman Vanesa , Stecher Daniel , Ceballos Ana , Remes Lenicov Federico 
Published: December 2022

Abstract

Background
Monocyte activation is a driver of inflammation in the course of chronic HIV infection. Prostaglandin E2 (PGE2) is known to mediate anti-inflammatory effects, notably the inhibition of tumor necrosis factor-α (TNF-α) production by monocytes. We aim to investigate the effects of PGE2 on activation of monocytes in chronic HIV infection and the mechanisms through which PGE2 modulates their inflammatory signature.

Methods
We recruited a group of people with HIV (PWH) and matched healthy uninfected persons. We compared plasma levels of PGE2, monocyte activation, and sensitivity of monocytes to the inhibitory actions mediated by PGE2.

Results
We found increased plasma levels of PGE2 in PWH, and an activated phenotype in circulating monocytes, compared with uninfected individuals. Monocytes from PWH showed a significant resistance to the inhibitory actions mediated by PGE2; the concentration of PGE2 able to inhibit 50% of the production of TNF-α by lipopolysaccharide-stimulated monocytes was 10 times higher in PWH compared with uninfected controls. Furthermore, the expression of phosphodiesterase 4B, a negative regulator of PGE2 activity, was significantly increased in monocytes from PWH.

Conclusions
Resistance to the inhibitory actions mediated by PGE2 could account, at least in part, for the inflammatory profile of circulating monocytes in PWH.
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
Authors: Díez-Domingo Javier , Sáez-Llorens Xavier , Rodriguez-Weber Miguel A , Epalza Cristina , Chatterjee Archana , Chiu Cheng-Hsun , Lin Chien-Yu , Berry Andrea A , Martinón-Torres Federico , Baquero-Artigao Fernando , Langley Joanne M , Ramos Amador José T , Domachowske Joseph B , Huang Li-Min , Chiu Nan-Chang , Esposito Susanna , Moris Philippe , Lien-Anh Nguyen Thi , Nikic Vanja , Woo Wayne , Zhou Yingjun , Dieussaert Ilse , Leach Amanda , Gonzalez Lopez Antonio , Vanhoutte Nicolas 
Published: December 2022

Abstract

Background
Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive. This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee adenovirus-RSV vaccine expressing 3 proteins (fusion, nucleoprotein, and M2-1), administered to 12–23-month-old RSV-seropositive children followed up for 2 years after vaccination.

Methods
Children were randomized to receive 2 doses of ChAd155-RSV or placebo (at a 1:1 ratio) (days 1 and 31). Doses escalated from 0.5 × 1010 (low dose [LD]) to 1.5 × 1010 (medium dose [MD]) to 5 × 1010 (high dose [HD]) viral particles after safety assessment. Study end points included anti–RSV-A neutralizing antibody (Nab) titers through year 1 and safety through year 2.

Results
Eighty-two participants were vaccinated, including 11, 14, and 18 in the RSV-LD, RSV-MD, and RSV-HD groups, respectively, and 39 in the placebo groups. Solicited adverse events were similar across groups, except for fever (more frequent with RSV-HD). Most fevers were mild (≤38.5°C). No vaccine-related serious adverse events or RSV-related hospitalizations were reported. There was a dose-dependent increase in RSV-A Nab titers in all groups after dose 1, without further increase after dose 2. RSV-A Nab titers remained higher than prevaccination levels at year 1.

Conclusions
Three ChAd155-RSV dosages were found to be well tolerated. A dose-dependent immune response was observed after dose 1, with no observed booster effect after dose 2. Further investigation of ChAd155-RSV in RSV-seronegative children is warranted.

Clinical Trials Registration
NCT02927873.
Target RNA-guided protease activity in type III-E CRISPR–Cas system
Authors: Wang Xiaoshen , Yu Guimei , Wen Yanan , An Qiyin , Li Xuzichao , Liao Fumeng , Lian Chengwei , Zhang Kai , Yin Hang , Wei Yong , Deng Zengqin , Zhang Heng 
Published: December 2022

Abstract
The type III-E CRISPR–Cas systems are newly identified adaptive immune systems in prokaryotes that use a single Cas7–11 protein to specifically cleave target RNA. Cas7–11 could associate with Csx29, a putative caspase-like protein encoded by the gene frequently found in the type III-E loci, suggesting a functional linkage between the RNase and protease activities in type III-E systems. Here, we demonstrated that target RNA recognition would stimulate the proteolytic activity of Csx29, and protein Csx30 is the endogenous substrate. More interestingly, while the cognate target RNA recognition would activate Csx29, non-cognate target RNA with the complementary 3′ anti-tag sequence inhibits the enzymatic activity. Csx30 could bind to the sigma factor RpoE, which may initiate the stress response after proteolytic cleavage. Combined with biochemical and structural studies, we have elucidated the mechanisms underlying the target RNA-guided proteolytic activity of Csx29. Our work will guide further developments leveraging this simple RNA targeting system for RNA and protein-related applications.
Site-directed biochemical analyses reveal that the switchable C-terminus of Rpc31 contributes to RNA polymerase III transcription initiation
Authors: Shekhar Arvind Chandra , Sun Yuan-En , Khoo Seok-Kooi , Lin Yu-Chun , Malau Ester Betaria , Chang Wei-Hau , Chen Hung-Ta 
Published: December 2022

Abstract
Rpc31 is a subunit in the TFIIE-related Rpc82/34/31 heterotrimeric subcomplex of Saccharomyces cerevisiae RNA polymerase III (pol III). Structural analyses of pol III have indicated that the N-terminal region of Rpc31 anchors on Rpc82 and further interacts with the polymerase core and stalk subcomplex. However, structural and functional information for the C-terminal region of Rpc31 is sparse. We conducted a mutational analysis on Rpc31, which uncovered a functional peptide adjacent to the highly conserved Asp-Glu-rich acidic C-terminus. This C-terminal peptide region, termed ‘pre-acidic’, is important for optimal cell growth, tRNA synthesis, and stable association of Rpc31 in the pre-initiation complex (PIC). Our site-directed photo-cross-linking to map protein interactions within the PIC reveal that this pre-acidic region specifically targets Rpc34 during transcription initiation, but also interacts with the DNA entry surface in free pol III. Thus, we have uncovered a switchable Rpc31 C-terminal region that functions in an initiation-specific protein interaction for pol III transcription.
The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results From a Randomized Controlled Trial
Authors: Cassidy Rachel N , Tidey Jennifer W , Jackson Kristina M , Cioe Patricia A , Murphy Sharon E , Krishnan-Sarin Suchitra , Hatsukami Dorothy , Colby Suzanne M 
Published: December 2022

AbstractIntroductionAs the science base around the potential benefits of a reduced-nicotine standard for cigarettes grows, information on the potential effects on adolescent smokers is a high priority. The aim of this randomized trial was to test the influence of 3-week exposure to reduced nicotine cigarettes in a sample of adolescent daily smokers.Aims and MethodsIn this double-blind, two-arm, randomized controlled trial (NCT0258731), following a 1-week baseline, adolescent daily smokers not currently intending to quit (ages 15–19 years, n = 66 randomized) were urn randomized to use either very low nicotine content (VLNC; 0.4 mg/g; n = 33) or normal nicotine content (NNC, 15.8 mg/g; n = 33) research cigarettes for 3 weeks. Participants attended five study sessions at our clinical laboratory. The primary outcome was average total cigarettes smoked per day (CPD; including both study and non-study cigarettes) at week 3.ResultsStepwise regression results demonstrated that compared with NNC cigarettes (n = 31), assignment to VLNC cigarettes (n = 29), was associated with 2.4 fewer CPD on average than NNC assignment (p &lt; .05) week 3 when controlling for covariates (p &lt; .01, Cohen’s d = 0.52 n = 60 completed all procedures). VLNC cigarettes were also associated with lower levels of craving reduction than NNC cigarettes (Questionnaire on Smoking Urges Factor 2, p &lt; .05). No group differences were found for secondary outcomes.ConclusionsAdolescent participants assigned to VLNC use for 3 weeks smoked fewer total CPD relative to the NNC group. Overall, data suggest that a VLNC policy would reduce cigarette smoking in adolescents who smoke, but high rates of incomplete adherence suggest that youth may seek alternative sources of nicotine in this scenario.ImplicationsThe US Food and Drug Administration may enact a reduced-nicotine product standard that would affect all commercially available cigarettes. One important population affected by this policy would be adolescents who smoke. This study, the first clinical trial of VLNC cigarettes in adolescents, demonstrates that adolescents switched to VLNC cigarettes for 3 weeks reduced their CPD relative to the normal-nicotine cigarette control group, without leading to increased respiratory symptoms or increased withdrawal. Biomarkers indicated the use of other sources of nicotine, suggesting that such a policy will need to consider approaches to assist in transitioning away from smoking.
Using Daily Ratings to Examine Treatment Dose and Response in Cognitive Behavioral Therapy for Chronic Pain: A Secondary Analysis of the Co-Operative Pain Education and Self-Management Clinical Trial
Authors: MacLean R Ross , Buta Eugenia , Higgins Diana M , Driscoll Mary A , Edmond Sara N , LaChappelle Kathryn M , Ankawi Brett , Krein Sarah L , Piette John D , Heapy Alicia A 
Published: December 2022

Abstract

Background
Cognitive behavioral therapy for chronic pain (CBT-CP) has a strong evidence base, but little is known about when treatment benefits are achieved. The present study is a secondary analysis of individuals with chronic back pain recruited for a noninferiority trial comparing interactive voice response (IVR) CBT-CP with in-person CBT-CP.

Methods
On the basis of data from daily IVR surveys, a clinically meaningful change was defined as a 30% reduction in pain intensity (n = 108) or a 45% increase in daily steps (n = 104) compared with the baseline week. We identified individuals who achieved a meaningful change at any point during treatment, and then we compared those who maintained a meaningful change in their final treatment week (i.e., responders) with those who did not or who achieved a meaningful change but lapsed (i.e., nonresponders).

Results
During treatment, 46% of participants achieved a clinically meaningful decrease in pain intensity, and 66% achieved a clinically significant increase in number of steps per day. A total of 54% of patients were classified as responders in terms of decreases in pain intensity, and 70% were responders in terms of increases in step count. Survival analyses found that 50% of responders first achieved a clinically meaningful change by week 4 for pain intensity and week 2 for daily steps. Dropout and demographic variables were unrelated to responder status, and there was low agreement between the two measures of treatment response.

Conclusions
Collectively, results suggest that most responders improve within 4 weeks. Evaluating treatment response is highly specific to the outcome measure, with little correlation across outcomes.
Advances in drug therapy and delivery for cataract treatment
Authors: Lee Bryanna J. , Afshari Natalie A. 
Published: December 2022

Purpose of review
Cataract is one of the leading causes of blindness worldwide and surgery is the only available treatment. Pharmacological therapy has emerged as a potential approach to combat the global shortage of surgery due to a lack of access and resources. This review summarizes recent findings in pharmacological treatment and delivery, focusing on drugs that target oxidative stress and the aggregation of crystallins.

Recent findings
Antioxidants and oxysterols have been shown to improve or reverse lens opacity in cataract models. N-acetylcysteine amide and N-acetylcarnosine are two compounds that have increased bioavailability over their precursors, alleviating the challenges that have come with topical administration. Studies have shown promising results, with topical N-acetylcarnosine clinically decreasing lens opacity. Furthermore, lanosterol, and more recently 5-cholesten-3b,25-diol (VP1-001), have been reported to combat the aggregation of crystallins in vivo and ex vivo. Delivery has improved with the use of nanotechnology, but further research is needed to solidify these compounds’ therapeutic effects on cataracts and improve delivery methods to the lens.

Summary
Although further research in drug dosage, delivery, and mechanisms will need to be conducted, pharmacologic therapies have provided new strategies and treatments for the reversal of cataracts.
Closed-loop ventilation
Authors: Arnal Jean-Michel , Katayama Shinshu , Howard Christopher 
Published: December 2022

Purpose of review
The last 25 years have seen considerable development in modes of closed-loop ventilation and there are now several of them commercially available. They not only offer potential benefits for the individual patient, but may also improve the organization within the intensive care unit (ICU). Clinicians are showing both greater interest and willingness to address the issues of a caregiver shortage and overload of bedside work in the ICU. This article reviews the clinical benefits of using closed-loop ventilation modes, with a focus on control of oxygenation, lung protection, and weaning.

Recent findings
Closed-loop ventilation modes are able to maintain important physiological variables, such as oxygen saturation measured by pulse oximetry, tidal volume (VT), driving pressure (ΔP), and mechanical power (MP), within target ranges aimed at ensuring continuous lung protection. In addition, these modes adapt the ventilator support to the patient's needs, promoting diaphragm activity and preventing over-assistance. Some studies have shown the potential of these modes to reduce the duration of both weaning and mechanical ventilation.

Summary
Recent studies have primarily demonstrated the safety, efficacy, and feasibility of using closed-loop ventilation modes in the ICU and postsurgery patients. Large, multicenter randomized controlled trials are needed to assess their impact on important short- and long-term clinical outcomes, the organization of the ICU, and cost-effectiveness.
Successful Clinical Nurse Specialist Recruitment
Authors: Fischer-Cartlidge Erica , Short Kathleen 
Published: December 2022

Background
The future of the clinical nurse specialist (CNS) role depends on nurses enrolling in CNS programs and having access to clinical experiences. At 1 institution, challenges with CNS recruitment and variations in how students were precepted were noted. This article describes a successful CNS student program and its value in creating a talent pipeline.

Project
A revision to student placements was initiated to create a formalized program including enhanced academic partnerships, standardized expectations and goals, assigned clinical projects and end-of-semester presentations, appointment of a student coordinator, and structured preceptor preparation.

Outcomes
Outcomes included 100 placements for 50 different students; the primary source of recruitment for the organization is now prior students, with 17 being hired since program inception. A 325% increase was also noted in qualified preceptors. Student productivity increased, and 11 students were accepted for national presentations. Academic sites have reported increased satisfaction.

Conclusion
Organizations looking to increase CNS recruitment should consider the revision of their student program. A centralized CNS responsible for student experiences can ensure standardization and provide preceptor support. The CNSs have an essential role in securing their future nationally and can do so through growing new talent and aiding in preparation for practice.
HIV Pre-exposure Prophylaxis Services for Black and Hispanic or Latino Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women in THRIVE, 2015-2020
Authors: Tanner Mary R. , Zhu Weiming , Iqbal Kashif , Dominguez Kenneth L. , Yu Lei , Hayes Tameka D. , Wiener Jeffrey , Koenig Linda J. , Batey Scott , Burgess Samuel , Elamin Fatima , Fox Anthony , Price Ashley , Wood Lucila , Hoover Karen W. 
Published: December 2022

Background and setting:
From 2015 to 2020, the THRIVE project supported 7 US health departments to improve HIV prevention services for Black or African American (Black) and Hispanic or Latino gay, bisexual, and other men who have sex with men (GBM) and transgender women (TGW).

Methods:
We described services provided in the THRIVE PrEP continuum. Using Poisson regression models, we estimated associations between race or ethnicity and age and PrEP screening, linkage, and prescription. We examined associations between colocation of services and PrEP linkage and prescription for 2 sites.

Results:
THRIVE served 12,972 GBM without HIV; 37% of PrEP-eligible GBM were prescribed PrEP. THRIVE served 1185 TGW without HIV; 45% of PrEP-eligible TGW were prescribed PrEP. Black and Hispanic or Latino GBM were 29% (RR = 0.71, 95% CI: 0.66–0.77) and 19% (RR = 0.81, 95% CI: 0.75–0.87) less likely, respectively, to be prescribed PrEP than White GBM. GBM aged 18–24 years and 55 years or older were 19% (RR = 0.81, 95% CI: 0.75–0.87) and 22% (RR = 0.78, 95% CI: 0.67–0.9) less likely, respectively, to be prescribed PrEP compared with those aged 35–44 years. Colocated services were associated with a 54% (RR = 1.54, 95% CI: 1.44–1.64) and a 31% (RR = 1.31, 95% CI: 1.19–1.43) greater likelihood of PrEP linkage and prescription, respectively, compared with services at different locations.

Conclusions:
THRIVE provided PrEP to higher proportions of PrEP-eligible persons than current national estimates; however, PrEP use disparities persist. Colocation of services may be a useful component of jurisdictional strategies to increase PrEP coverage.
A novel fluorescently-labeled long-chain fatty acid analog for the study of fatty acid metabolism in cultured cells
Authors: Hara Yasuhiro , Hirano Ken-ichi 
Published: December 2022

Abstract123I-15-(p-iodophenyl)-(R,S)-methyl pentadecanoic acid (BMIPP) is a long-chain fatty acid (LCFA) analog developed to examine myocardial LCFA metabolism and has been used as a tracer for nuclear cardiology. However, its use is limited because of the specialized features of cardiac scintigraphy. In this study, a novel BMIPP-based probe was utilized, in which iodine-123 was replaced with a fluorescent compound, to extend the use of123I-BMIPP to a wider variety of cellsex vivo. To confirm that this fluorescent LCFA analog (fluorescent BMPP) was imported into cells, fluorescence-activated cell sorting (FACS) analysis and fluorescent cell imaging were performed using cultured cells. The analysis showed that the import of fluorescent BMPP into the cells occurred in a concentration-dependent manner. This import into cells was inhibited by Sulfosuccinimidyl Oleate in a dose-dependent manner, which is an inhibitor of CD36, a well-known LCFA transporter, suggesting that fluorescent BMPP could be imported into cells via the same pathway as LCFA. FACS and cell imaging intensities of the cells importing fluorescent BMPP were attenuated after incubation in the non-Alexa680-BMPP medium. These results suggest that fluorescent BMPP can be transported into and from cells, reflecting the metabolism of LCFA. Fluorescently-labeled BMPP has the potential to be used as a probe for studying LCFA metabolism in various cells.
Near-universal same day linkage to ART care among newly diagnosed adults living with HIV: A cross sectional study from primary health facilities, in urban Malawi
Authors: Chihana Rachel , Katumbi Chaplain , Dadabhai Sufia , Kaumba Agness , Mughogho Atusaye , Singano Victor , Mwapasa Victor , Malisita Ken 
Published: December 2022

AbstractMalawi HIV treatment guidelines recommend same-day antiretroviral therapy (ART) initiation. Overall 97.9 % of Malawians living with HIV (PLHIV) are on ART, same-day ART initiation prevalence and factors that facilitate it have not been fully described. We assessed same-day ART initiation and described individual, health system and health facility infrastructural factors at health facilities supported by expert clients (EC). ECs are lay PLHIV who support other PLHIV. The study was conducted in urban and semi-urban primary health facilities, in Blantyre, Malawi. It was a cross-sectional, descriptive survey of PLHIV and health facility leaders. Eligibility criteria included age ≥ 18 years, new diagnosis of HIV, received counselling from ECs, and offered same day ART. The study was conducted from December 2018 to June 2021, and 321 study participants enrolled. Mean age (standard deviation) was 33 years (10) with 59% females. In total, 315 (98.1%) initiated same day ART. Four participants did not because of mental unpreparedness, one wanted to try herbal medicine and one was concerned about stigma. Participants reported health facility accessibility (99%,318/321), privacy (91%, 292/321) and quality of counselling by EC as excellent (40%,128/321). Same day ART was nearly universal. Participants’ satisfaction with health services delivery, the presence of EC, and infrastructural characteristics such as good privacy were cited as reasons favoring same day linkage to ART. The most cited reason for not starting same day ART was mental unpreparedness.